A 13-year-old spayed female Domestic Shorthair presents w...

Thank you for reaching out regarding this complex case. A 13-year-old hyperthyroid cat with concurrent azotemia requires a very careful and methodical approach to methimazole initiation. The presence of mild chronic kidney disease (CKD) is a critical factor, as hyperthyroidism often masks underlying renal insufficiency due to its hyperdynamic state, artificially maintaining glomerular filtration rate (GFR).

Here's my initial recommended methimazole dosing strategy and subsequent monitoring plan:

Initial Methimazole Dosing Strategy

Given the palpable thyroid slip, significant T4 elevation (7.8 ug/dL), and classic clinical signs (weight loss, polyphagia), the diagnosis of hyperthyroidism is clear. However, the mild azotemia (creatinine 2.1 mg/dL) necessitates a conservative approach to methimazole.

Dose Selection: I recommend initiating methimazole at the lowest end of the typical starting range.

* Methimazole: 1.25 mg PO BID
Rationale:* Starting with a low dose minimizes the risk of a precipitous drop in GFR if the hyperthyroid state was significantly supporting renal function. This conservative approach allows us to gradually assess the impact of thyroid hormone normalization on renal parameters.

Administration: Ensure the owners understand to administer the medication consistently. While transdermal methimazole is an option, oral administration allows for more precise dose adjustments and is generally preferred for initial titration unless oral compliance is a significant issue.

Monitoring and Reassessment Plan

Close monitoring is paramount, particularly in the initial weeks.

Recheck Timing: The first recheck should be performed 2-4 weeks after initiating methimazole. I typically aim for 2 weeks in cases with concurrent azotemia to catch any renal decompensation early.

Diagnostics at Recheck:

* Total T4: To assess the therapeutic response to methimazole.
* Complete Biochemistry Panel: With particular attention to BUN, creatinine, and symmetric dimethylarginine (SDMA). SDMA is a more sensitive marker for detecting early declines in GFR and can be very helpful here.
* Urinalysis: Including specific gravity, to further assess renal concentrating ability.
* Complete Blood Count (CBC): To monitor for potential adverse effects of methimazole, such as neutropenia or anemia, although these are less common with low initial doses.

Interpretation and Next Steps:

* Scenario A: Total T4 normalizes AND renal values remain stable or improve.
* This is the ideal outcome. If renal values are stable after 2-4 weeks on methimazole, the cat is a good candidate for definitive therapy such as I-131 radioactive iodine, which remains the gold standard. We would continue methimazole at 1.25 mg PO BID until definitive therapy is pursued.
* Scenario B: Total T4 normalizes, BUT renal values worsen (e.g., creatinine increases).
* This indicates that the hyperthyroidism was indeed masking underlying CKD. We would then need to prioritize renal function.
* Options include: further reducing the methimazole dose (e.g., to 1.25 mg PO once daily or even every other day) to allow the T4 to be mildly elevated but hopefully stabilize renal function; transitioning to a renal diet; or considering other CKD management strategies. This cat would likely not be a candidate for I-131 unless renal function stabilizes at a T4 level that is still mildly elevated. The goal shifts to finding the "sweet spot" where thyroid function is adequately controlled without severely compromising renal function.
* Scenario C: Total T4 remains elevated, AND renal values remain stable.
* If the cat is tolerating the methimazole well and renal values are stable, we can consider a cautious dose increase (e.g., to 2.5 mg PO BID) and re-evaluate in another 2-4 weeks.

Additional Considerations

* Dietary Management: While on methimazole, ensure the cat is on a high-quality, palatable diet. If renal values worsen, a prescription renal diet will be indicated, but this decision should be made after assessing the impact of methimazole.
* Owner Communication: It's crucial to explain to the owners the delicate balance between treating hyperthyroidism and managing concurrent CKD. Emphasize the importance of the recheck appointments and the potential for renal values to worsen as thyroid function normalizes.

This methodical approach allows us to achieve thyroid control while carefully monitoring and mitigating the risks associated with concurrent CKD.

Confidence Level: High confidence. This is a common clinical scenario, and the strategy aligns with current best practices in small animal internal medicine.